Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
Completed
Daiichi Sankyo Inc.
Phase 4
2005-11-01
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy
administered to heterozygous familial pediatric patients 10 through 17 years of age who are
on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin,
simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy.
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
Completed
Daiichi Sankyo, Inc.
Phase 4
2005-11-01
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy
administered to heterozygous familial pediatric patients 10 through 17 years of age who are
on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin,
simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy.
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
Completed
Daiichi Sankyo Inc.
Phase 3
2004-06-01
The purpose of the study is to see how safe and effective and tolerable the use of
colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in
combination with other anti-diabetic drugs.
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
Completed
Daiichi Sankyo, Inc.
Phase 3
2004-06-01
The purpose of the study is to see how safe and effective and tolerable the use of
colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in
combination with other anti-diabetic drugs.
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
Completed
Daiichi Sankyo Inc.
Phase 2
2005-06-01
This study is designed to assess the potential mechanism of action by which WelChol®
(colesevelam) may improve blood glucose control in patients with type 2 diabetes
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
Completed
Daiichi Sankyo, Inc.
Phase 2
2005-06-01
This study is designed to assess the potential mechanism of action by which WelChol®
(colesevelam) may improve blood glucose control in patients with type 2 diabetes
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
